Keywords
Anti-infectives
Cost and Cost Analysis
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the pharmacoeconomic impact of the COVID-19 pandemic on the consumption of antimicrobials in a hospital, providing information on the use of these medications in tragedy situations. Methods: Secondary-based retrospective observational study in a hospital in Ceará, analyzing data from 2019 to 2021, divided into three periods corresponding to the pandemic. We assessed the impact of COVID-19 costs on the consumption of antimicrobials, through partial cost-consequence analysis. Data were summarized in figures with averages, medians and 95% confidence intervals. Kruskal-Wallis and ANOVA tests were used to compare averages between periods. Approved by the Research Ethics Committee. Results: We observed an 84% increase in the cost of antimicrobials in the third peak of the pandemic, coinciding with the increase in mortality rates. The consumption of antimicrobial bottles followed the increase in total cost, with statistically significant results (p-value < 0.05). Conclusion: We conclude that the third pandemic period had a significantly greater impact on the use and cost of antimicrobials. We recommend multicenter, clinically focused studies on this topic.
References
BRAÚNA C, et al. Farmacoeconomia aplicada ao tratamento medicamentoso para a COVID-19 em um hospital campanha. Revista Eletrônica Acervo Saúde, 2021; 13(2): e5971.
Boletim Epidemiológico: Doença pelo novo coronavírus (COVID-19). Governo do Estado do Ceará. 2021. Disponível em: https://www.saude.ce.gov.br/wp-content/uploads/sites/9/2020/02/BOLETIM-COVID-19- N30_16.09.2.pdf. Acessado em: 10 de outubro de 2022.
CONOVER, WJ. 1971. Practical nonparametric statistics. London, Sidney: Wiley & Sons. 462p.
DE WAELE J, et al. Antimicrobial stewardship in ICUs during the COVID-19 pandemic: back to the 90s? Intensive Care Med., 2021; 47: 104-106.
DORN F, et al. The challenge of estimating the direct and indirect effects of COVID-19 interventions - Toward an integrated economic and epidemiological approach. Econ Hum Biol, 2023; 49: 101198.
HOLGUÍN H, et al. Intervenciones farmacéuticas y desenlaces clínicos en un programa de gerenciamiento de antimicrobianos. Revista Chilena Infectologia, 2020; 37(4): 343-348.
HUTTNER BD, et al. COVID-19: don't neglect antimicrobial stewardship principles! Clinical Microbiology and Infection, 2020; 26: 808-810.
LYNCH C, et al. Antimicrobial stewardship: a COVID casualty? Journal of Hospital Infection, 2020; 106: 401- 403.
LUCIEN MAB, et al. Antibiotics and antimicrobial resistance in the COVID-19 era: Perspective from resource-limited settings. Int J Infect Dis, 2021; 104: 250-254.
MARTIN E, et al. Antimicrobial stewardship challenges and innovative initiatives in the acute hospital setting during the COVID-19 pandemic. Journal Antimicrobial Chemotherapy, 2021; 76(1): 272-275.
MICHELI G, et al. The Hidden Cost of COVID-19: Focus on Antimicrobial Resistance in Blood stream Infections. Microorganisms, 2023; 11(5): 1299.
MONTRUCCHIO G, et al. Choosing wisely: what is the actual role of antimicrobial stewardship in Intensive Care Units? Minerva Anestesiologica, 2019; 85: 71-82.
MOURA E, et al. Covid-19: temporal evolution and immunization in the three epidemiological waves, Brazil, 2020–2022. Rev Saude Publica, 2022; 56: 105.
NATHWANI D, et al. Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review. Antimicrobial Resistance and Infection Control, 2019; 35(8).
O'TOOLE RF. The interface between COVID-19 and bacterial healthcare-associated infections. Clin Microbiol Infect, 2021; 27(12): 1772-1776.
SANTOS H, et al. Gastos públicos com internações hospitalares para tratamento da covid-19 no Brasil em 2020. Revista de Saúde Pública, 2021; 55-52.
SOUSA GJB, et al. Mortality and survival of COVID-19. Epidemiology and Infection, 2020; 148(123): 1-6.
TONIN FS, et al. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. Pharm Pract (Granada), 2021; 19(1): 2302.
TROMBOLD N, AWAD D. The economic opportunity of departmental training during pandemic scenarios: Concepts and analyses. Am J Health Syst Pharm, 2021; 78(23): 2164-2166.
VAN DER POL S, et al. Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review. Pharmacoeconomics, 2021; 39(12): 1411-1427.